Ken Cacciatore analyst

Currently out of the existing stock ratings of Ken Cacciatore, 122 are a BUY (81.88%), 26 are a HOLD (17.45%), 1 are a SELL (0.67%).

Ken Cacciatore

Work Performance Price Targets & Ratings Chart

Analyst Ken Cacciatore, carries an average stock price target met ratio of 40.21% that have a potential upside of 34.76% achieved within 413 days. Previously, Ken Cacciatore worked at TD COWEN.

Ken Cacciatore’s has documented 290 price targets and ratings displayed on 38 stocks. The coverage was on Healthcare, Consumer Defensive, Industrials sectors.

Most recent stock forecast was given on OCUL, Ocular Therapeutix at 08-Nov-2023.

Wall Street Analyst Ken Cacciatore

Analyst best performing recommendations are on ENDP (ENDO INTERNATIONAL PLC).
The best stock recommendation documented was for ENDP (ENDO INTERNATIONAL PLC) at 2/26/2020. The price target of $5 was fulfilled within 8 days with a profit of $1.35 (21.26%) receiving and performance score of 26.57.

Average potential price target upside

ADMS Adamas Pharmaceuticals AGN Allergan plc BCRX BioCryst Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd ENDP Endo International PLC HZNP Horizon Pharma PLC JAZZ Jazz Pharmaceuticals PLC TEVA Teva Pharma Industries Ltd ADR AMRN Amarin PLC ARQT Arcutis Biotherapeutics  CHRS Coherus BioSciences MYL Viatris VTRS Viatris AMAG AMAG Pharmaceuticals AUPH Aurinia Pharmaceuticals RVNC Revance The EYPT Eyepoint Pharmaceuticals ISEE IVERIC bio TXMD TherapeuticsMD AERI Aerie Pharmaceuticals BLCO Bausch + Lomb Corp BHC Bausch Health Companies OCUL Ocular Therapeutix TAK Takeda Pharmaceutical Co Ltd ADR ARAV Aravive IMPL Impel Neuropharma KMPH KemPharm MNTA Momenta Pharmaceuticals OYST Oyster Point Pharma SUPN Supernus Pharmaceuticals VRCA Verrica Pharmaceuticals ADM Archer-Daniels-Midland Company AER AerCap Holdings NV DERM Journey Medical Corp LQDA Liquidia Technologies MOLN Molecular Partners AG ADR OPTN OptiNose TARA Protara Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 29-Nov-2017

$8.5

$0.28 (3.41%)

4 years 7 months 26 days ago
(18-Nov-2021)

0/3 (0%)

$0.33 (4.04%)

Hold Since 13-Oct-2021

$8

$-0.22 (-2.68%)

$10

4 years 9 months 1 days ago
(13-Oct-2021)

1/7 (14.29%)

$-0.07 (-0.87%)

6

Buy Since 12-Jan-2016

$8

$-0.22 (-2.68%)

$7

4 years 9 months 1 days ago
(13-Oct-2021)

4/5 (80%)

$-0.07 (-0.87%)

95

Buy Since 17-Aug-2017

$14

4 years 9 months 1 days ago
(13-Oct-2021)

3/7 (42.86%)

$9.25 (194.74%)

87

Buy

$6

$-2.22 (-27.01%)

$20

4 years 9 months 2 days ago
(12-Oct-2021)

0/2 (0%)

$3.2 (23.94%)

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Ken Cacciatore?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?